Back to Journals » OncoTargets and Therapy » Volume 9

B-cell-specific Moloney murine leukemia virus integration site 1: potential stratification factor and therapeutic target for epithelial ovarian cancer

Authors Zhao Q, Gui T, Qian Q, Li L, Shen K

Received 29 March 2016

Accepted for publication 10 June 2016

Published 22 August 2016 Volume 2016:9 Pages 5203—5208

DOI https://doi.org/10.2147/OTT.S109443

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Lucy Goodman

Peer reviewer comments 3

Editor who approved publication: Professor Min Li


Qianying Zhao,1,* Ting Gui,1,* Qiuhong Qian,1,2 Lei Li,1 Keng Shen1

1Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 2Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Shandong, People’s Republic of China

*These authors contributed equally to this work

Abstract: Epithelial ovarian cancer, a vexing challenge for clinical management, still lacks biomarkers for early diagnosis, precise stratification, and prognostic evaluation of patients. B-cell-specific Moloney murine leukemia virus integration site 1 (BMI1), a member of the polycomb group of proteins, engages in diverse cellular processes, including proliferation, differentiation, senescence, and stem cell renewal. In addition, BMI1, as a cancer stem-cell marker, participates in tumorigenesis through various pathways. Rewardingly, recent studies have also revealed a relationship between BMI1 expression and the clinical grade/stage, therapy response, and survival outcome in a majority of human malignancies, including epithelial ovarian cancer. Therefore, BMI1 might serve as a potential stratification factor and treatment target for epithelial ovarian cancer, pending evidence from further investigations.

Keywords: B-cell-specific Moloney murine leukemia virus integration site 1 (BMI1), epithelial ovarian cancer (EOC), molecular marker, treatment target, cancer stem-cell, tumor heterogeneity

Corrigendum for this paper has been published.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]